Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice

Jae Geun Hyun, Goo Lee, Jeffrey B. Brown, Gery R. Grimm, Yueming Tang, Navhda Mittal, Ramanarao Dirisina, Zheng Zhang, Jonathan P. Fryer, Joel V. Weinstock, Andrew D. Luster, Terrence A. Barrett*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Abstract

Background: Colitis in interleukin (IL)-10-/- mice is a CD4 + T helper 1 (TH1)-mediated disease characterized by intermittent, transmural inflammation reminiscent of human Crohn's disease. In this study, we investigated the hypothesis that production of the CXC chemokine CXCL10 (interferon [IFN]γ-inducible protein 10) enhances induction of inflammatory responses in draining lymph nodes (LNs) and promotes colonic T H1 cell recruitment. Methods: Colitis was induced in B6 IL-10 -/- mice. Mice were given anti-CXCL10 mAb in 2-week intervals before and after peak colitis. Colitis severity was graded and cytokine/chemokine levels were analyzed by real-time polymerase chain reaction. Cell yields were quantitated and effector cell recruitment was assessed by recovery of transferred DO 11.10 TH1 cells shortly (72 h) after transfer. Results: Treatment with anti-CXCL10 during colitis development decreased clinical and histologic disease severity as well as cytokine/chemokine mRNA and accumulation of mononuclear cells in LNs and colon. Treatment of mice with severe colitis reduced colitis scores and cell yields to lesser degrees. Anti-CXCL10 specifically decreased recruitment of transferred TH1 cells into mesenteric LNs (MLNs) and colon of IL-10-/- mice by 75% (P < 0.05). Conclusion: These results suggest that CXCL10 plays a dual role in colitis development by enhancing TH1 cell generation in inductive sites and promoting effector cell recruitment to inflamed tissue. Blockade of CXCL10 may be a useful adjunct to remission-inducing therapies in inflammatory bowel disease (IBD) by impairing disease recurrence through selective inhibition of effector cell generation and trafficking in vivo.

Original languageEnglish (US)
Pages (from-to)799-805
Number of pages7
JournalInflammatory bowel diseases
Volume11
Issue number9
DOIs
StatePublished - Sep 2005

Keywords

  • CXCL10
  • Colitis
  • Interleukin-10
  • Knockout
  • Piroxicam

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Fingerprint Dive into the research topics of 'Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice'. Together they form a unique fingerprint.

Cite this